Mupirocin

Generic name
Mupirocin
Brand name
ATC Code
D06AX09
Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Skin infections
  • Cutaneous
    • 1 month up to 18 years
      [2]

      • apply two or three times daily for a maximum of 10 days
Nasal infection (including MRSA)
  • Nasal
    • 1 month up to 18 years
      [2]

      • apply 2-3 times daily in both nostrils

      • Duration of treatment:

        For 5-7 days. Do not use for longer than 10 days because of the development of resistance.

      • In cases of MRSA eradication, mupirocin should be prescribed along with additional measures in consultation with the hospital hygiene department or an infectiologist.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

In cases of MRSA eradication, mupirocin should be prescribed along with additional measures in consultation with the hospital hygiene department or an infectiologist

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTIBIOTICS FOR TOPICAL USE

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. GlaxoSmithKline BV, SPC Bactroban huidzalf en neuszalf (RVG 11651 en 13761) 16-04-2020, www.geneesmiddeleninformatiebank.nl
  3. GlaxoSmithKline, DHPC Bactroban 26-03-2018, https://www.cbg-meb.nl/documenten/brieven/2018/03/26/dhpc-bactroban

Changes

Therapeutic Drug Monitoring


Overdose